New Breast Cancer Tumor Suppressor Identified
6/28/2011
Researchers have identified a protein long known to regulate gene expression as a potent suppressor of breast cancer growth. Their study, in the journal Oncogene, is the first to demonstrate how this protein, known as Runx3, accomplishes this feat...
Study Supports Immediate Breast Reconstruction After Mastectomy
6/28/2011
For women undergoing mastectomy for breast cancer, immediate breast reconstruction has a low risk of complications-including serious complications related to radiation therapy-and does not cause undue delays in cancer treatment, reports a study in the July issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS)...
Scientists Investigate Whether A Blood Test Can Help To Detect Breast Cancer
6/28/2011
A study spearheaded by the University of Leicester aims to find out whether a blood test can detect cancer, earlier than current methods, in women with a strong family history of breast cancer. Leicestershire cancer research charity Hope Against Cancer is supporting the study with a £90,000 Maria Tilton Research Fellowship based at the University of Leicester...
Main Results Of The Full Phase I/II Study Of Amphinex(R)
6/28/2011
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex® in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin. The primary objective of this dose escalation study is to assess the maximum tolerated dose of the new component Amphinex®...
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced the submission to the European (EMA) and American (FDA) Drug Agencies of an application for orphan medicinal product designation for clonidine Lauriad™, in the prevention of radiotherapy-induced oral mucositis in patients w...
Local Death Rate From Breast Cancer Exceeds State And National Averages
6/27/2011
In a newly released report, communities and populations of women most in need of breast health and breast cancer services are identified, with recommendations offered on how to help reduce the high death rates in Northeast Ohio. The 2011 Community Profile produced by Susan G. Komen for Cure Northeast Ohio Affiliate unveils new data related to its 22 county service area...
EpiCept Receives Initial FDA Comments On Application For Ceplene(R) Special Protocol Assessment
6/27/2011
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced that it has received initial written responses from the U.S. Food and Drug Administration (FDA) regarding the Company's application for a Special Protocol Assessment (SPA) of the Ceplene® (histamine dihydrochloride) Phase III protocol...
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for ADCETRIS™ (brentuximab vedotin) for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and relapsed or refractory sy...
FDA Modifies Dosing Recommendations For Erythropoiesis-Stimulating Agents
6/27/2011
The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death...
to-BBB Starts Clinical Trial In Patients With Brain Metastases
6/27/2011
to-BBB, the Dutch brain drug delivery company, is pleased to announce that it has received approval to start treating patients with brain metastases with its lead product 2B3-101 in a Phase I/II clinical trial. Based on its proprietary G-Technology®, to-BBB is developing its lead compound 2B3-101, brain-targeted doxorubicin liposomes...